Corbus Pharmaceuticals Holdings, Inc. (3371.F)
Frankfurt · EUR · Healthcare · Biotechnology
€3.45 (+2.55%) as of
Key statistics
- Market cap
- 66.80M
- EPS (TTM)
- -5.2300
- Dividend yield
- 0.00%
- 52-week range
- 3.2860 – 14.2000
- Beta
- 2.63
- Profit margin
- 0.00%
- Volume
- 200.00
About Corbus Pharmaceuticals Holdings, Inc.
Corbus Pharmaceuticals Holdings, Inc., a clinical stage company, develops and commercializes therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E; and CRB-913, a peripherally restricted cannabinoid type-1 receptor inverse agonist for the treatment of obesity. The company was incorporated in 2009 and is headquartered in Norwood, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Norwood, MA, United States
- Employees
- 36
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.